全文获取类型
收费全文 | 1605篇 |
免费 | 166篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 85篇 |
妇产科学 | 37篇 |
基础医学 | 252篇 |
口腔科学 | 36篇 |
临床医学 | 198篇 |
内科学 | 284篇 |
皮肤病学 | 29篇 |
神经病学 | 71篇 |
特种医学 | 45篇 |
外科学 | 169篇 |
综合类 | 45篇 |
一般理论 | 1篇 |
预防医学 | 145篇 |
眼科学 | 23篇 |
药学 | 131篇 |
肿瘤学 | 205篇 |
出版年
2018年 | 25篇 |
2017年 | 15篇 |
2015年 | 23篇 |
2014年 | 40篇 |
2013年 | 45篇 |
2012年 | 28篇 |
2011年 | 40篇 |
2010年 | 38篇 |
2009年 | 54篇 |
2008年 | 38篇 |
2007年 | 38篇 |
2006年 | 32篇 |
2005年 | 47篇 |
2004年 | 42篇 |
2003年 | 33篇 |
2002年 | 31篇 |
2001年 | 27篇 |
2000年 | 44篇 |
1999年 | 47篇 |
1998年 | 33篇 |
1997年 | 38篇 |
1996年 | 44篇 |
1995年 | 38篇 |
1994年 | 33篇 |
1993年 | 35篇 |
1992年 | 25篇 |
1991年 | 34篇 |
1990年 | 33篇 |
1989年 | 51篇 |
1988年 | 53篇 |
1987年 | 48篇 |
1986年 | 41篇 |
1985年 | 42篇 |
1984年 | 36篇 |
1983年 | 36篇 |
1982年 | 28篇 |
1981年 | 18篇 |
1980年 | 19篇 |
1979年 | 25篇 |
1978年 | 33篇 |
1977年 | 25篇 |
1974年 | 25篇 |
1973年 | 32篇 |
1972年 | 26篇 |
1971年 | 14篇 |
1970年 | 23篇 |
1969年 | 15篇 |
1968年 | 14篇 |
1967年 | 16篇 |
1966年 | 19篇 |
排序方式: 共有1774条查询结果,搜索用时 203 毫秒
81.
A premature infant developed pericardial effusion four days after the insertion of a 25-gauge silastic percutaneous central venous catheter. The effusion contained parenteral nutrition fluid and resolved rapidly after withdrawal of the catheter. Pericardial effusion is a potential complication of percutaneous, as well as surgically placed, central venous catheters. 相似文献
82.
Twenty-six adolescents, aged 13–18 years, with severe congenital heart disease were matched for sex, age and living area with 26 adolescents with repaired atrial septal defect and regarded as physically fit. These two groups were compared according to somatic condition, psychopathology, psychosocial functioning and chronic family difficulties. A higher rate of psychiatric problems in the complex group, an association between psychosocial functioning and physical capacity, as well as an association between psychosocial functioning and chronic family difficulties were observed. These findings suggest that physical capacity is of crucial importance for mental health and functioning of adolescents with congenital heart disease. The association with chronic family difficulties also suggests that a comprehensive biopsychosocial approach is necessary in the treatment and rehabilitation of these patients. 相似文献
83.
PG Chatelain Kabi Pharmacia International Growth Study 《Acta paediatrica (Oslo, Norway : 1992)》1993,82(S392):79-81
Using the database from the Kabi Pharmacia International Growth Study, 105 patients with intrauterine growth retardation (IUGR) (82 males, 23 females) and 45 with Silver-Russell syndrome (SRS) (32 males, 13 females) with persistent postnatal growth failure were studied. Patients with IUGR had a birth length and birth weight more than 2 SD below the mean for gestational age. Their height deficit at the start of GH treatment was -3.0 SDS at a median chronological age of 8.7 years and a median bone age of 7.0 years. Mean paternal and maternal heights were 166 and 153 cm, respectively. The median dose of GH was 0.5 IU/kg/week, given at a median frequency of five injections/week. The median height SDS for chronological age after 1, 2 and 3 years of GH treatment were -2.5, -2.1 and -1.9, respectively. In the 45 patients with SRS, median chronological age and median bone age at the start of treatment were 6.7 and 3.2 years, respectively, and mean paternal and maternal heights were 167.5 and 160 cm, respectively. The median dose of GH was 0.7 IU/kg/week, given at a median frequency of six injections/week. The median height SDS for chronological age at the start of treatment and after 1, 2 and 3 years were -3.5, -2.9, -2.8 and -2.2, respectively. Although the criteria used by physicians when diagnosing SRS were not controlled or verified in this study, it appears that patients with SRS can be differentiated from those with IUGR with persistent growth failure by their reduced bone age for chronological age at the start of treatment, and by the fact that patients with SRS tended to be born to parents of normal height. GH treatment in both groups induced catch-up growth, though long-term follow-up studies will be required to assess the effects of treatment on final height. 相似文献
84.
Adults who were small at birth have been reported to have higher systolic blood pressure and risk of ischaemic heart disease in later life. Conversely, in 616 subjects of less than 34 weeks' gestation and 1850 g birth weight, systolic and diastolic blood pressures at 7.5 to 8 years of age decreased with decreasing weight for gestational age and were not related to birth weight. These data do not support the view that fetal growth retardation before 34 weeks programmes for increased blood pressure in later life. 相似文献
85.
86.
ULTRASTRUCTURE OF THE HUMAN AMNION, CHORION AND FETAL SKIN 总被引:2,自引:0,他引:2
87.
The somatomedins. A new class of growth-regulating hormones? 总被引:2,自引:0,他引:2
88.
Evans WK Dahrouge S Stapleton J Quinn C Pollock D Waterfield B Lister D Hansel F Smith A 《Lung cancer (Amsterdam, Netherlands)》2000,28(2):85-95
OBJECTIVE: Although it is commonly assumed that clinical trials are more costly than standard therapy, there have been no previous studies of the cost of conducting phase II trials in lung cancer. We retrospectively analyzed two National Cancer Institute of Canada phase II trials in previously untreated small cell lung cancer (SCLC) to determine the costs of conducting the trials in a cancer treatment centre. Both studies were clinical trials undertaken as part of the NCIC's Investigational New Drug program: IND 69 and IND 50 evaluated docetaxel (taxotere) and gemcitabine, respectively. METHODS: data management costs in a Canadian cancer treatment centre were determined from the time estimates provided by data managers to complete various protocol related tasks. Nursing and pharmacy personnel measured the time and supplies necessary to prepare and administer the chemotherapy. Physician fees were determined from the type and number of care visits required by the clinical protocols. Laboratory tests and imaging studies were costed according to the Ontario Health Insurance Plan (OHIP) Schedule of Fees and Benefits. To estimate whether phase II trials are more costly than standard treatment, we determined the cost of four cycles of VP-16-cisplatin, a standard treatment for SCLC. RESULTS: The total cost of performing the docetaxel study was $18443 for an average cost per case of $1317 and an average cost per treatment cycle of $683. The gemcitabine study cost more, due to the fact that the drug proved to be active against SCLC and more cycles of therapy were administered to a larger number of patients. Laboratory and administration costs were also higher, because of the drug administration schedule. The total cost of this study was estimated to be $64670 and the average cost per patient entered was $2230 with an average cost per treatment cycle of $898. In comparison, the estimated cost of four cycles of VP-16-cisplatin chemotherapy was $3948 or $987 per treatment cycle. The major cost drivers in the clinical trials were laboratory and imaging tests which made up 17 and 39%, respectively, of the costs of the taxotere study, and 29 and 27%, respectively, for the gemcitabine study. Data management costs contributed 21 and 13% of the total costs, respectively. CONCLUSION: As the main cost drivers in these phase II clinical trials are laboratory and imaging tests, the cost of clinical trials could potentially be reduced by ensuring that only essential tests are required by protocol. Not surprisingly, the cost of conducting a trial of an active agent is greater than for an inactive agent, because more patients are treated and each patient receives more treatment. The implications for the per-case funding of phase II clinical trials are discussed. 相似文献
89.
Pedersen LM Terslev L SŁrensen PG Stokholm KH 《Medical oncology (Northwood, London, England)》2000,17(2):117-122
Transcapillary escape rate of albumin was determined in 22 patients with different malignancies. In addition, urinary albumin
excretion rate was measured in 24-h urine samples using a sensitive immunoassay. Increased urinary albumin excretion was defined
as ≥20 μg/min according to conventional standards. Renal glomerular filtration and tubular function was estimated by51Cr-EDTA plasma clearance and urinary beta 2-microglobulin, respectively. Median urinary albumin excretion rate was 15.0 μg/min
(range 6–510 μg/min) and the frequency of increased urinary albumin excretion was 41%. This agrees with other studies showing
increased albuminuria in several types of malignant diseases. Patients with advanced disease (tumour, node, metastasis (TNM)
stage II–IV) had a significantly higher urinary albumin excretion rate than patients with localized disease (TNM stage I).
Serum creatinine, glomerular filtration rate and urinary beta 2-microglobulin were all within normal limits. Median transcapillary
escape rate of albumin was 5.5%/h (range 2–8%/h) and this level is comparable with values in healthy subjects. There was no
significant difference in transcapillary escape rate between patients with elevated urinary albumin excretion and the normoalbuminuric
group. Median value of the absolut outflux of albumin was 10.6 g/h with similar levels in patients with increased urinary
albumin excretion and patients with normoalbuminuria. Our results indicate a high prevalence of minor glomerular dysfunction
with a slightly elevated urinary albumin excretion in patients with malignancies. The normal endothelial function, as estimated
by the transcapillary escape rate of albumin, suggests an overal unaffected capillary permeability and increased urinary albumin
loss appears to be an isolated renal phenomenon in cancer patients. 相似文献
90.